

Nepal Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal				
2. Grant number: 1819-NPL-09a-X / 15-NPL-08d-Y				
3. Date of Decision Letter: 21 December 2017				
4. Date of the Partnership Framework Agreement: 22 August 2014				
5. Programme title: New vaccine support (NVS), Measles-Rubella Second Dose Routine				
6. Vaccine type: Measles-Rubella				
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 doses per vial, LYOPHILISED				
8. Programme duration¹: 2015 - 2019				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)				
	2015-2017	2018	2019	Total ²
Programme Budget (US\$)	834,093 ³	3,500	8,000	845,593
10. Vaccine introduction grant (in US\$): a VIG of US\$ 546,500 was disbursed on 28 March 2015				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2015-2017	2018		
Number of Measles vaccines doses		11,800		
Annual Amounts (US\$)	834,093 ⁵	3,500		
12. Procurement agency: UNICEF				
13. Self-procurement: Not applicable				
14. Co-financing obligations: Not applicable, but see section 18 below.				
15. Operational support for campaigns: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

16. Additional reporting requirements:	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions:	
Country has presented an official request to Gavi to switch from measles vaccine to measles-rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2018
Number of doses of vaccines for Measles Second Dose approved by Gavi.	11,800
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	3,186
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	5,155
Number of doses of Measles-Rubella vaccine to be funded by country.	6,645
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	4,106
<p>In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.</p> <p>In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.</p>	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2017